22536-61-4

Basic information

• Product Name: 2-Chloro-5-methylpyrimidine
• Synonyms: Pyrimidine, 2-chloro-5-methyl- (8CI,9CI);2-Chloro-5-methylpyrimidine;2-Chloro-5-methyl-1,3-diazine;2-Chloro-5-MethylpyriMidine, 97+%
• CAS NO: 22536-61-4
• Molecular Formula: C₅H₅ClN₂
• Molecular Weight: 128.56
• EINECS: 1592732-453-0
• Product Categories: PYRIMIDINE;pharmacetical;Pyrimidine series;Heterocycle-Pyrimidine series
• Mol File: 22536-61-4.mol

Chemical Properties

• Melting Point: 89-92℃
• Boiling Point: 239.2 °C at 760 mmHg
• Flash Point: 121.5 °C
• Appearance: /Solid
• Density: 1.234 g/cm³
• Vapor Pressure: 0.0628mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -1.03±0.22(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-Chloro-5-methylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-methylpyrimidine(22536-61-4)
• EPA Substance Registry System: 2-Chloro-5-methylpyrimidine(22536-61-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 22536-61-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Chloro-5-methylpyrimidine is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for further functionalization and modification, enabling the creation of a wide range of molecules with diverse properties and applications.
Used as a Catalytic Agent:
Due to its reactivity, 2-Chloro-5-methylpyrimidine can act as a catalyst in certain chemical reactions. It can facilitate and enhance the rate of these reactions, making it an essential component in various industrial processes.
Used in Petrochemical Additives:
In the petrochemical industry, 2-Chloro-5-methylpyrimidine is utilized as an additive to improve the performance and properties of various products. Its incorporation can lead to enhanced stability, reactivity, or other desired characteristics in the final product.
Used in Synthetic Chemistry:
As a versatile building block, 2-Chloro-5-methylpyrimidine is widely used in synthetic chemistry for the development of new compounds and materials. Its unique structure and reactivity make it a valuable tool for researchers and chemists in their quest to create novel substances with specific properties and functions.
Used as an Intermediate for Pharmaceutical Applications:
2-Chloro-5-methylpyrimidine is also employed as an intermediate in the pharmaceutical industry. Its structure can be further modified and functionalized to create active pharmaceutical ingredients (APIs) with potential therapeutic applications. 2-Chloro-5-methylpyrimidine serves as a starting point for the development of new drugs and medications, contributing to the advancement of medical treatments and healthcare solutions.

InChI:InChI=1/C5H5ClN2/c1-4-2-7-5(6)8-3-4/h2-3H,1H3

Upstream product

• 1780-36-5 5-methyl-2,4,6-trichloropyrimidine 
• 75-24-1 trimethylaluminum 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 7732-18-5 water 
• 65-71-4 thymin 
• 41398-85-0 5-methyl-pyrimidin-2-(1H)-one 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 

Downstream Products

• 50840-23-8 5-methylpyrimidin-2-amine 
• 127524-21-4 3-Chloro-4-(5-methyl-pyrimidin-2-yloxy)-phenylamine 
• 77232-48-5 5-methyl-2-(phenyl)pyrimidine 
• 113669-56-0 N,N-dimethyl-2-<(5'-methylpyridinium-2'-yl)thio>ethylamine 
• 122372-13-8 5-methyl-2-(β-styryl)pyrimidine 
• 104355-16-0 Cyano-[5-methyl-1H-pyrimidin-(2E)-ylidene]-acetic acid ethyl ester 
• 151673-94-8 5-methyl-1,2-dihydro-2-pyrimidinyldenemalononitrile 
• 69034-11-3 2-chloro-5-trichloromethylpyrimidine 
• 99420-75-4 5-methyl-2-pyrimidinecarboxylic acid 
• 142730-00-5 2-carbethoxy-5-methylpyrimidine 
• 122372-22-9 1-(5-methylpyrimidin-2-yl)ethanone 
• 69034-12-4 2-chloro-5-(trifluoromethyl)pyrimidine 
• 83767-80-0 5-trifluoromethyl-pyrimidin-2-one 
• 83767-78-6 2-ethylthio-5-trifluoromethylpyrimidine 

Relevant articles and documents

Synthesis method 2 -fluoro -5 -trifluoromethyl pyrimidine

The invention relates to the technical field of drug synthesis, and provides a synthesis method of 2 -fluoro -5 -trifluoromethyl pyrimidine. 5 - Methyluracil is used as a raw material and is subjected to cyclic chlorination reaction. Redox reaction, chlorination reaction and fluorination reaction obtain the target product, the process is simple, the raw materials are cheap and easily available, the yield is high, and no heavy metal pollution is generated in the whole process. In the chlorination reaction, phosphorus oxychloride is used for chlorination, chlorine is used for chlorination in the chlorination reaction, the cost of the chlorination reaction is low, phosphorus pentachloride is used for recycling phosphorus oxychloride in the cyclochlorination reaction, and the reaction cost can be further reduced.

VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Discovery of (10 R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17- tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]- benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations

Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during treatment eventually develops. Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation. In addition, some patients progress due to cancer metastasis in the brain. Using structure-based drug design, lipophilic efficiency, and physical-property-based optimization, highly potent macrocyclic ALK inhibitors were prepared with good absorption, distribution, metabolism, and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability. These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations. Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms. This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

[4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases

The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.

BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Bipiperidinyl compounds of the formula I, are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE

The invention relates to compounds of formula (I). Said compounds are suitable for producing medicaments for the prophylaxis and treatment of diseases, the progression of which involves increased activity of IκB kinase.